Baidu
map

“新型举国体制:政府与企业的合作” 2020中国抗病毒药物创新大会在苏州召开

2020-07-11 E药经理人 E药经理人

“2020中国抗病毒药物创新大会”在苏州举行

2020年7月11日,由中国医药生物技术协会、中国医药企业管理协会支持指导,苏州市相城区人民政府主办,苏州市相城区黄埭镇人民政府、苏州市相城区发展和改革委员会、苏州市相城区卫生健康委员会、E药经理人、中国医疗健康产业投资50人论坛承办的“2020中国抗病毒药物创新大会”在苏州举行。中国工程院院士樊代明、张伯礼、李校堃,中国疾病预防控制中心流行病学首席科学家曾光等专家学者出席会议,并以线上线下相结合的方式发表主题演讲。据悉,超过200位来自医疗健康领域的科学家、企业家、投资人参加了本次会议。

长久以来,人类与病毒进行着不懈斗争。从天花、肝炎,到艾滋病、SARS、MERS,再到当下的新型冠状病毒,人类一直致力开发预防它们的疫苗或抑制它们的药物。但是病毒独特的结构和增殖方式,让药物研发面临天然挑战,尤其是要应对突发传染病,在短期内研制出疫苗或发现特效药难度更大。

面对挑战,我国自“十一五”,就明确提出把生物医药创新,建设一批重大疾病防治疫苗和基因工程药物产业化示范工程,增强自主创新能力作为国家战略目标。近期,习近平总书记又再次提出,要从体制机制上增强科技创新和应急应变能力,加快构建关键核心技术攻关新型举国体制,补短板、强弱项、堵漏洞,提升科技创新体系化能力。由此,我国抗病毒药物(疫苗)研制也开始步入全新的发展阶段。

在这一背景之下,2020中国抗病毒药物创新大会应用而生,借此机会,汇聚政府主管部门、专家学者,以及产、学、研、资的代表,探讨具有中国特色的抗病毒药物和疫苗的研发创新模式。

会议伊始,由中国工程院院士、温州医科大学校长兼病毒研究院院长李校堃,中国医药企业管理协会名誉会长郭云沛,中国医药生物技术协会理事长、信达生物制药集团董事长兼总裁俞德超致辞。郭云沛在致辞中指出,在此次疫情之下,对抗病毒药物/疫苗研发和创新已经得到更加广泛的关注,全球研发创新机构正在加快速度,我们只有通过协同创新,才能为人类健康做出更大的贡献。俞德超在致辞中表示,药物创新不仅要有研发投入、人才队伍支撑,更关键的是要通过此次疫情,使我国的医药卫生体制机制得到一次根本性的完善。

在全球疫情还未得到有效控制的当下,曾光教授围绕“全球新冠疫情研判与下一步中国防疫策略”这一主题,分析了全球疫情发展的趋势走向,同时也为中国下一阶段防疫提出了建设性策略。樊代明院士与张伯礼院士则从抗疫后的医学发展和中医药抗疫的优势与特点与现场观众进行了交流。而来自清华大学交叉医学院国际生物经济中心主任、科技部中国生物技术发展中心原主任王宏广则从顶层设计角度就如何为疫情防控提供制度支撑、科技支撑进行了主题发言。

此外,本次会议也邀请了全球著名医药创新服务机构科睿唯安生命科学与制药事业部首席科学家王刚,以及歌礼制药董事长兼首席执行官、中国科学院上海药物研究所新药产业兼职研究员吴劲梓分别就“全球抗病毒药物研发全景图及未来趋势展望”和“中国抗病毒药物研发的顶层设计:新冠疫情给我们的教训和启思”发表了洞察。

值得一提的是,本次大会特设“抗病毒药物/疫苗研究进展发布”环节,来自江苏省疾控中心、山东大学药、上海医药、康希诺生物等8家研究机构、医药企业分别披露了各自在抗新冠病毒药物和疫苗的研发进展情况。

会议最后,以“完善国家平战结合的抗疫药物/疫苗科研攻关和供应保障体系,如何更好发挥企业作用”、“面对病毒大流行,产、学、研、资如何打破藩篱,实现有效的共享合作”为主题举行了两场圆桌讨论。吉利德科学全球副总裁、中国区总经理罗永庆,前沿生物董事长谢东,中国疾病预防控制中心全球公共卫生中心主任董小平,重庆医科大学第二附属医院院长任红,君联资本董事总经理洪坦等13位来自政府、学界、产业界、投资界的代表参与讨论。

本次大会还向与会者介绍了相城生物医药国际研发社区的基本情况和产业发展政策,并举行了中国医药企业管理协会与苏州市相城区医药产业创新合作平台揭牌仪式。

 

 

 

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1285886, encodeId=3475128588685, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292528, encodeId=17b11292528a6, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363364, encodeId=d1721363364bd, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456308, encodeId=26c714563080f, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802537, encodeId=89f580253e95, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200711/8cf1a2946fc14af2bc879ee50d546249/04951632b612493ab5278b090b1c095c.jpg, createdBy=be935399814, createdName=果m, createdTime=Sat Jul 11 21:37:35 CST 2020, time=2020-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802520, encodeId=2e0980252061, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>很好的会议, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Sat Jul 11 17:13:10 CST 2020, time=2020-07-11, status=1, ipAttribution=)]
    2020-07-13 lilianxiang
  2. [GetPortalCommentsPageByObjectIdResponse(id=1285886, encodeId=3475128588685, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292528, encodeId=17b11292528a6, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363364, encodeId=d1721363364bd, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456308, encodeId=26c714563080f, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802537, encodeId=89f580253e95, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200711/8cf1a2946fc14af2bc879ee50d546249/04951632b612493ab5278b090b1c095c.jpg, createdBy=be935399814, createdName=果m, createdTime=Sat Jul 11 21:37:35 CST 2020, time=2020-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802520, encodeId=2e0980252061, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>很好的会议, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Sat Jul 11 17:13:10 CST 2020, time=2020-07-11, status=1, ipAttribution=)]
    2020-07-13 yahu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1285886, encodeId=3475128588685, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292528, encodeId=17b11292528a6, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363364, encodeId=d1721363364bd, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456308, encodeId=26c714563080f, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802537, encodeId=89f580253e95, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200711/8cf1a2946fc14af2bc879ee50d546249/04951632b612493ab5278b090b1c095c.jpg, createdBy=be935399814, createdName=果m, createdTime=Sat Jul 11 21:37:35 CST 2020, time=2020-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802520, encodeId=2e0980252061, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>很好的会议, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Sat Jul 11 17:13:10 CST 2020, time=2020-07-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1285886, encodeId=3475128588685, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292528, encodeId=17b11292528a6, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363364, encodeId=d1721363364bd, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456308, encodeId=26c714563080f, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802537, encodeId=89f580253e95, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200711/8cf1a2946fc14af2bc879ee50d546249/04951632b612493ab5278b090b1c095c.jpg, createdBy=be935399814, createdName=果m, createdTime=Sat Jul 11 21:37:35 CST 2020, time=2020-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802520, encodeId=2e0980252061, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>很好的会议, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Sat Jul 11 17:13:10 CST 2020, time=2020-07-11, status=1, ipAttribution=)]
    2020-07-13 hyf030
  5. [GetPortalCommentsPageByObjectIdResponse(id=1285886, encodeId=3475128588685, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292528, encodeId=17b11292528a6, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363364, encodeId=d1721363364bd, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456308, encodeId=26c714563080f, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802537, encodeId=89f580253e95, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200711/8cf1a2946fc14af2bc879ee50d546249/04951632b612493ab5278b090b1c095c.jpg, createdBy=be935399814, createdName=果m, createdTime=Sat Jul 11 21:37:35 CST 2020, time=2020-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802520, encodeId=2e0980252061, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>很好的会议, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Sat Jul 11 17:13:10 CST 2020, time=2020-07-11, status=1, ipAttribution=)]
    2020-07-11 果m

    学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1285886, encodeId=3475128588685, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292528, encodeId=17b11292528a6, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363364, encodeId=d1721363364bd, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456308, encodeId=26c714563080f, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Mon Jul 13 07:11:45 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802537, encodeId=89f580253e95, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200711/8cf1a2946fc14af2bc879ee50d546249/04951632b612493ab5278b090b1c095c.jpg, createdBy=be935399814, createdName=果m, createdTime=Sat Jul 11 21:37:35 CST 2020, time=2020-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802520, encodeId=2e0980252061, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>很好的会议, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Sat Jul 11 17:13:10 CST 2020, time=2020-07-11, status=1, ipAttribution=)]
    2020-07-11 神盾医疗局局长Jack

    #新冠肺炎#很好的会议

    0

Baidu
map
Baidu
map
Baidu
map